Unknown

Dataset Information

0

Expanding the Noonan spectrum/RASopathy NGS panel: Benefits of adding NF1 and SPRED1.


ABSTRACT: BACKGROUND:RASopathies are a group of disorders caused by disruptions to the RAS-MAPK pathway. Despite being in the same pathway, Neurofibromatosis Type 1 (NF1) and Legius syndrome (LS) typically present with phenotypes distinct from Noonan spectrum disorders (NSDs). However, some NF1/LS individuals also exhibit NSD phenotypes, often referred to as Neurofibromatosis-Noonan syndrome (NFNS), and may be mistakenly evaluated for NSDs, delaying diagnosis, and affecting patient management. METHODS:A derivation cohort of 28 patients with a prior negative NSD panel and either NFNS or a suspicion of NSD and café-au-lait spots underwent NF1 and SPRED1 sequencing. To further determine the utility and burden of adding these genes, a validation cohort of 505 patients with a suspected RASopathy were tested on a 14-gene RASopathy-associated panel. RESULTS:In the derivation cohort, six (21%) patients had disease-causing NF1 or SPRED1 variants. In the validation cohort, 11 (2%) patients had disease-causing variants and 15 (3%) had variants of uncertain significance in NF1 or SPRED1. Of those with disease-causing variants, 5/17 only had an NSD diagnosis. CONCLUSIONS:Adding NF1 and SPRED1 to RASopathy panels can speed diagnosis and improve patient management, without significantly increasing the burden of inconclusive results.

SUBMITTER: Witkowski L 

PROVIDER: S-EPMC7196473 | biostudies-literature | 2020 Apr

REPOSITORIES: biostudies-literature

altmetric image

Publications

Expanding the Noonan spectrum/RASopathy NGS panel: Benefits of adding NF1 and SPRED1.

Witkowski Leora L   Dillon Mitchell W MW   Murphy Elissa E   S Lebo Matthew M   Mason-Suares Heather H  

Molecular genetics & genomic medicine 20200227 4


<h4>Background</h4>RASopathies are a group of disorders caused by disruptions to the RAS-MAPK pathway. Despite being in the same pathway, Neurofibromatosis Type 1 (NF1) and Legius syndrome (LS) typically present with phenotypes distinct from Noonan spectrum disorders (NSDs). However, some NF1/LS individuals also exhibit NSD phenotypes, often referred to as Neurofibromatosis-Noonan syndrome (NFNS), and may be mistakenly evaluated for NSDs, delaying diagnosis, and affecting patient management.<h4>  ...[more]

Similar Datasets

| S-EPMC8191452 | biostudies-literature
| S-EPMC6119537 | biostudies-literature
| S-EPMC5357488 | biostudies-literature
| S-EPMC4916843 | biostudies-literature
| S-EPMC1285166 | biostudies-literature
2020-07-31 | GSE151417 | GEO
| S-EPMC3306856 | biostudies-literature